Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good morning and welcome to Nextmune. Nextmune Second Quarter Earnings Call 2026. I am Olli, Group CEO, and together with me, I have our CFO, Carly Boudry, presenting our results for the second quarter. We continue building upon a good start of the year and report our second quarter with strong revenue and earnings growth as well as margin expansion. Our double-digit growth in the quarter is well ahead of the global animal health market. Coupled with strong adjusted EBITDA growth. We have also closed four acquisitions year-to-date and continue to advance our M&A pipeline with active discussions across all four segments. We have also achieved recognition for our ESG achievements with a new 'AAA' ESG rating from MSCI. Turning to the numbers in a bit more detail. We report 17% revenue growth and reach €121.6 million in revenue in the second quarter. Organic growth was 12%, with double-digit growth in Specialty Pharma, MedTech, and Veterinary Services. Our three largest segments saw a 6% contribution from acquisitions. And we had a 1% negative impact from currency movements. Adjusted EBITDA grew 17% to €29.7 million, with strong earnings growth across all four segments. Margin improved to 24.5%, driven by the consolidation of acquired businesses in the MedTech dental segment. Moving into Specialty Pharma, the segment delivers another strong quarter with organic growth of 14%. All four therapeutic areas deliver solid growth, and the strongest contribution in this quarter comes from Specialty Pharmaceuticals and specialized nutrition. We completed another successful sales campaign together with a US retailer. A similar campaign took place in the third quarter of 2025. These campaigns make growth vary between quarters, but the underlying business momentum continues. Good. During the quarter, we also launched 25 new products and opened our new R&D hub in France focused on the development of biological pharmaceuticals. Adjusted EBITDA grew 13% to €15.4 million, and we maintain a strong margin at 30.1%. Before we move on to the other segments, in our last quarter presentation, we gave you a short business snapshot about our MedTech dental platform and veterinary services' upcoming market expansion. In this quarter, we will continue our series of business snapshots by providing more insights into our innovation work within Specialty Pharma. Thank you Olli, and let me spend a few minutes on innovation, as I have had the pleasure for the last couple of months to be close to the Specialty Pharma team and segment, working as ad interim responsible for the Specialty Pharma segment. So, innovation is really at the heart of Nextmune's Specialty Pharma growth strategy. Innovation is one of the four pillars of our strategy. We focus on identifying unmet clinical needs and bringing differentiated products to market through internal R&D, scientific collaborations, and selective partnerships. This approach is delivering consistent output. Over the last 12 months, we've launched 75 new products and have more than 60 additional products in the pipeline. These products span multiple therapeutic areas and technologies, creating a balanced and sustainable innovation engine. As you can see from the quarterly launch cadence, innovation remains a continuous process, supporting long-term organic growth and reinforcing our leadership positions in attractive specialty markets. Let me now make our innovation strategy a little bit more tangible by looking at two of our therapeutic areas: allergy and specialty pharmaceuticals in allergy. Our ambition is to further strengthen our position as a global leader in veterinary allergology. PAX2 is a great example of that, and a further innovation of the PAX2 Pet Allergy Explorer that we launched three years ago by incorporating an additional 25 novel allergens identified by Nextmune. We're further enhancing the clinical value of our diagnostics platform, with commercial launch targeted around one of the world's largest dermatology congresses. ESVD-ECVD. In the autumn of 2026, in Specialty Pharmaceuticals, our ambition is to build a differentiated, compounded drugs portfolio through internal innovation, combined with partnerships with biotech companies and leading universities. One example of how we're delivering on this ambition is through our newly established division. Nextmune Bio. Nextmune Bio significantly strengthens our biological capabilities through a dedicated R&D team, a development facility, and an established biologics pipeline, creating a platform for future prescription innovation across therapeutic areas. Our innovation strategy extends beyond prescription diagnostics to prescription drugs and our entire OTC portfolio, where we continue to develop differentiated products addressing unmet needs in dermatology. Our ambition is to strengthen our leading position in skin and ear care through continued innovation, while leveraging that expertise to expand into adjacent therapeutic areas. A good example is IryLac, our first ophthalmology OTC product. It expands our presence into eye care with a preservative-free formulation designed to restore tear film stability and improve patient comfort. Our ambition is to continue building a differentiated portfolio of nutritional solutions based on scientific evidence and targeted innovation. A good example is UNA-10, a microbiota-focused supplement supporting gut health. Its differentiated formulation enables targeted release and reflects our focus on translating science into products that address real clinical needs. Across our therapeutic areas. Our approach is consistent: focused R&D investments, a deep understanding of unmet clinical needs, and a steady pipeline of differentiated innovations. Together, these capabilities provide a strong foundation for sustainable organic growth in specialty pharma. Thank you very much. Moving on to MedTech, the segment returned to double-digit growth of 11%, with double-digit growth in both the dental and orthopedic businesses. As expected, our US orthopedic business returned to growth on the back of our consistent efforts to strengthen commercial performance and operations despite unchanged market conditions. Our focus on education to unlock long-term market growth in both orthopedics and dental remains. And we educated over 1,300 veterinarians in the quarter. Adjusted EBITA grew 27% to €11.2 million, and adjusted EBITA margin improved to 25.8%, mainly driven by the consolidation of acquired businesses in the veterinary dental part of the segment. Moving on to Veterinary Services, the segment continues its momentum and delivered a strong organic growth of 10%, with continued momentum in new member growth and strategic partnerships. At the end of the quarter, we reached 11,900 members across four continents. Adjusted EBITDA grew 18% and adjusted EBITDA margin reached 28.2%. As expected, this was somewhat lower than the previous year due to mixed effects from acquisitions and our communicated growth investments in new markets and services. Looking into diagnostics, the segment delivered 7% organic growth in the quarter. Adjusted EBITDA grew 32% and the adjusted EBITDA margin of 29% was driven by product mix with a higher level of extraction sales. We communicated earlier this year that we entered 2026 with a stronger M&A pipeline, and we see continued improvement in our M&A activities and momentum. We have year-to-date closed four acquisitions and continue to have a very active pipeline going forward as well across all four segments. The latest acquisition is the crematorium business, Verona Pet, within our diagnostic business in Italy. From a sustainability perspective, we continue to deliver our sustainability agenda in our Spring initiative. We received further recognition through the rating upgrade from AA to AAA within MSCI. We are now among the top 1% of MSCI rated peers globally and a leader among 153 health care equipment and supplies companies. This concludes the run-through of the quarter, and I will hand over to Kalua for deeper insights into the financials. Thank you, Jen. And let's jump into the financials. More specifically on the numbers for the second quarter, adjusted EBITDA in the second quarter was €29.7 million, corresponding to an increase of 17%. And that translates into an adjusted EBITDA margin equal to 24.5%. The margin increase compared to the same period last year is primarily a result of positive margin development. In our MedTech dental business, central costs amounted to €3.0 million, an increase from €2.2 million last year. This increase is mainly the result of expenses related to our long-term incentive programs. In total, €0.8 million in the quarter, and during the end of the second quarter, we implemented LTI 26 as approved by the Annual General Meeting in April, where we will see the full effect from the third quarter and onwards. These are non-cash IFRS expenses that will recur for the duration of the three-year programs. We report an operating profit of €22.3 million, a significant 54% increase from last year's result of €14.5 million. Items affecting comparability decreased in the quarter compared to the same period last year and totaled -€0.9 million. The majority of items affecting comparability relates to acquisition costs in Veterinary Services and in Diagnostics, totaling -€0.5 million. Net financial items amounted to -€8.0 million and consisted of three main parts: financing expenses of -€3.1 million, with an average interest rate of 3.9% during the quarter, partly offset by interest income of €0.2 million, a quarterly discounting impact of -€1.0 million, and a negative impact of €2.5 million from probability adjustments related to contingent considerations, mainly relating to new acquisitions. A negative impact of €1.6 million from exchange rate effects on revaluation of debt. Income tax expense for the quarter was -5.5 million, at an effective tax rate of 39% in the quarter. The tax expense as a percentage of pre-tax profit was negatively affected by probability adjustments related to contingent considerations and other non-deductible expenses. In total, this results in a profit for the period of €8.8 million, with an earnings per share of €0.02 for the quarter. Looking at cash flow for the second quarter, cash flow from operating activities reached €3.8 million, and the operating cash flow was negatively impacted by the timing of taxes paid and Net Working Capital effects. Net working capital amounted to €114.1 million at the end of the quarter, equal to 26% of revenue, an increase from €92.8 million at the end of the first quarter, which equaled 21% of revenue. The majority of the €21.3 million increase in working capital relates to increasing receivables after a strong finish to the quarter, as well as specific inventory buildup to support continued customer demand; cash flow from investing activities amounted to -€22.9 million, primarily consisting of acquisitions and earn-out payments. And finally, cash flow from financing activities was €20.5 million from proceeds from borrowings. At the end of the quarter. Net debt amounted to 273.7 million, which is up from 258.4 million at the end of the first quarter. Cash and cash equivalents amounted to 51.6 million, an increase compared to 50.4 million at the end of March, with external lending of 261.7 million at the end of the second quarter. All in all, this resulted in the leverage at the end of the quarter equal to 2.1x, unchanged compared to the end of the first quarter. And we continue to be well capitalized with an ability to execute on our strengthened acquisition pipeline, and with this, I conclude the financial review. I hand the word back to Ali for concluding remarks. Thank you, Juan. Summarizing the first half of 2026, I am pleased to see that improved execution of our key strategic focus areas has been successful. The quarter was strong with double-digit organic revenue growth, strong earnings growth, and improved margins, all well ahead of the global animal health market. We've closed four acquisitions year to date and have a highly active pipeline across all four segments. For the remainder of the year, during the second half, our focus will be on executing our M&A pipeline while continuing to drive strong organic growth and building a strong culture. Thank you for your attention. And with that, we can open up for Q&A.
If you wish to ask a question, please dial star five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Kaavya Deshpande from UBS. Please go ahead.
Good morning. Thank you for taking my questions. I have two, please. My first one was on U.S. I-Vet Ortho growth. So your comps look a little bit tougher in the second half of the year, or more like flattish growth versus double-digit declines in H1. And should we continue to see organic growth at a low single-digit level here, or is your strategy making you think that an acceleration might actually be possible here? And my second question was around the spread of margins between dental and I-Vet Ortho. It seems like this is quite different today to where it used to be, given the investments in ortho and the margin expansion in dental; would you be able to give us a sense of where they sit today? Please.
Thank you for the questions. I think if I start off with your first question, we expect that the changes we've implemented to drive continued growth in the US orthopedic business will continue. And we expect continuous low single-digit growth in the second half of the year as well. We still see unchanged market conditions. The market is soft. So depending on how the market develops as well, that could of course impact that number. We are very happy and confident with the management team and the execution of the changes we implemented over the last six months regarding margins. Overall, for the business, I believe we have a good margin business within MedTech in total, and if we take orthopedics and dental, more specifically in orthopedics, as communicated, we have taken deliberate and focused investments to make sure that we get back to growth as I just mentioned. But as we continue on the growth path, those investments will ensure that we continue to grow and improve margins steadily over time within orthopedics, and in dental, we continue to improve the margins both operationally and in the second quarter. There has also been an impact with the addition of the company that we acquired in June last year. And we get the full effect this quarter that has a higher margin profile than the rest of the MedTech and the dental business. But all in all, we see that MedTech is developing positively and we are confident that with continued growth, we will see a steady margin improvement in the segment over time.
Thank you very much. If I could just ask a quick follow-up on that dental margin, please. How far do you feel you are from the ideal margin for that business? I understand the gross margin in general is a little bit lower in dental than for orthopedics. But I mean, could we feasibly ever see the dental margin sort of in the 30s, like vet also used to be before the US market decline.
We definitely believe that the dental part of MedTech will continue to see margin improvement. Then we will continue to invest for future growth as well. Because I think, as you see in this report and what we believe going forward, there are a lot of interesting opportunities in the dental segment where we want to make sure that we invest for continued solid growth in our dental business. That said, we do see that margins will improve over time. Also in the dental area within MedTech.
Understood. Thank you very much.
The next question comes from Arvid Nicotra from DNB Carnegie. Please go ahead.
Good morning and thanks for taking my questions. So the first one on Specialty Pharmaceuticals, I was just wondering if you can quantify the contribution from the national sales campaign. And I guess just overall, how would you characterize the underlying demand in the different subsegments here? And then secondly, on M&A, you seem to be increasingly positive on the outlook here and highlighting a highly active pipeline. So should we expect the activity to accelerate in the second half of the year? And I guess overall, how would you characterize the size of the opportunities that you're more upbeat on for the near term? I'll start there. Thanks.
Morning. So let me address the first question regarding Specialty Pharmaceuticals. We have not disclosed the total size of the national sales program that we conducted in Q2 of this year compared to Q3 of last year. The program implemented this year is a little bit larger than the program we did last year. So there is a positive effect from that as already communicated during the presentation. We could see an effect of the program being implemented in Q2 having a good contribution. Whereas we will see, you could say, the flip side in Q3 where we had the program last year. That said, the organic growth, adjusting for the national sales program in the second quarter of this year, was 9%. And going back to the second part of the question, I am encouraged that we see good growth in underlying momentum in all the therapeutic areas within Specialty Pharmaceuticals. We did have some very strong growth in US Specialty Pharmaceuticals on the back of the national sales program. But the other therapeutic areas grew well, as also seen in the quarter and for the first half year. Moving on to the second question. As we said before, we entered 2026 with a stronger pipeline than before, we have built upon that pipeline the last few months, and I feel positive about the opportunities of welcoming new, strong businesses and entrepreneurs during the second half of this year, but it is difficult to speculate exactly when and how, because key for us is always to make sure it is the right acquisition at the right valuation and so forth. So, all in all, we are positive about the conversations and the attractiveness we can offer strong entrepreneurs in the animal health space. In terms of size, it is a mixed bag. We see both smaller bolt-ons and bigger acquisitions in the pipeline. Exactly when and how and if they materialize depends on how the development goes in the second half of the year, but we remain optimistic. We remain equally optimistic about the business momentum we currently have, as well as our M&A momentum.
Great. Understood. Thank you. I'll jump back in the queue.
The next question comes from John Unwin from Barclays. Please go ahead.
Hi. Good morning and thank you for taking my questions. I actually just wanted to follow up on the dental margin question. I think you gave some good detail, but when you acquired I-Vet, I think the margin in that business was in the high teens to low 20s. Is that materially different today? Have you managed to improve it? I am thinking excluding the LTM acquisition. Just thinking more about iM3 specifically. After my first question and then in veterinary services, over what time frame do you expect the investments that you're doing in organic growth to be complete? And also, how long will it take for these investments to translate into the organic growth you expect to see? And then my third question is on orthopedics in MedTech. The market you said in the US remains soft, but how are you thinking about the market and the growth possibilities outside the US in the back half of this year and into next year. Thank you.
Uh thank you. And let's start with the margin question on dental and excluding M&A. So yes, we have seen a positive margin trajectory since the acquisition of I-Vet and the other bolt-on acquisitions that we have done in dental. So, there has been an underlying positive margin trajectory in the dental business, excluding Allergan as well. So the second question in terms of Veterinary Services and the investments and the margin, I think we talked a bit more deeply into the market and service expansions we are doing in the last quarter of the presentation. As we see, the margin of Veterinary Services is improving quarter by quarter on the back of the development of the business. We believe that a healthy margin in veterinary services should be around 28%, which is where it is today. It normally takes us 12 to 18 months to break even in a new market. When we enter that from that perspective, in terms of the third question, which I believe was in the MedTech ortho segment outside of the US. We have now had two quarters with double-digit growth outside of the US markets in Europe and APAC. We see strong momentum in the business and are the combination of our market position, product portfolio, and quality. And with the team we have, we believe we can continue strong momentum outside of the US for the rest of the year as well.
Great. Thank you very much.
The next question comes from Adrian Amlin from Nordea. Please go ahead.
Hi guys. Good morning. I just have one question. Really. It's been a couple of months. Now, with you as acting head of Specialty Pharmaceuticals, perhaps. Could you give us an update on the search for this permanent segment head? And if not, if this extends for a longer period, what are your plans for the segment?
So the recruitment for a new head of Specialty Pharmaceuticals is ongoing. It has been a couple of months, but when you look into recruiting a senior hire for the management team, you want to ensure you take the time to find the right profile and candidate for not just Specialty Pharma, but Nextmune as a whole. At the same time, I am extremely happy with how the team has managed and developed the business during the last six months. I would like to remind you that we run a very decentralized model. So, our four therapeutic areas have strong leaders, which is reflected in the performance of the business these last two quarters. So we want to make sure we find the right candidate and it takes the time it takes to do so. During that time, I am very confident that the Specialty Pharma business will continue to build upon its business momentum. And as you saw in the presentation, there is a lot of exciting innovation, product development, and so forth going on in the segment to enable future growth.
Right. Okay. Fair enough. Just one quick follow-up. Maybe I missed this, but you have some 60 products in the pipeline, right? For Specialty Pharmaceuticals, is there anything especially of interest in that pipeline that we should take note of?
In terms of our development pipeline, it is a mix of both. Improved formulations of existing products, you can say lifecycle improvements, as well as larger or more exciting innovations. But it is a mixed portfolio across our pipeline of roughly 60 products today. But in the near term.
Thank you very much, guys.
As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Sten Gustafsson from ABG Sundal Collier. Please go ahead.
Good morning. To start off with a clarification, perhaps you could comment on the expected growth rate for the MedTech division in the second half. I did not catch the number, so could you please comment on that? And then secondly, with regards to the sort of transformation that you have done in the U.S. Regarding the MedTech business, are there more actions for you to take there, or is this sort of now all set up and we are basically seeing your execution on actions you have already taken? Thank you.
Hi, Diane. Thanks for the question. So I think when you, from an operational standpoint, look into implementing changes and improving a business, it is continuous improvement. So although we have done some, if you call them, larger changes, we have a new head of MedTech in place and so forth. I believe the team and the rest of the management team will continue to tweak the business to make sure we are where we want to be and continuously improve. And that's the same case across all four of our segments. So I am expecting continuous tweaks and changes to make sure that we are where we want to be and that we are prepared to unlock the potential and the white space within MedTech, orthopedics, and dental going forward in terms of growth in MedTech in the second half. We don't give specific guidance, but we believe that the changes we have implemented in US orthopedics, as well as the business momentum we have across MedTech in general with double-digit growth in the quarter, allow us to enter the second half of the year with good momentum. But as I also said, the US orthopedic market remains soft; depending on the development of that, you could see headwinds or tailwinds as well. But in general, we are confident with the performance of the team, we are confident with the products we have in our portfolio, and we believe that we have the right management in place to make the continuous enhancements and improvements in the business to unlock future growth.
Perfect. Thank you very much for your answers. Thank you.
The next question comes from Kavya Deshpande from UBS. Please go ahead.
Hi. Sorry. Me again. I was wondering if I could ask a follow-up on the operating receivables point, please. I was just wondering if the increase was related in any way to the transformation strategy in ortho. I know you've been trying to push on education efforts and get new GPs implanting and similar technologies. That sometimes comes with working capital effects. Yes, I was wondering if there was a link there and if so, should we continue to expect high receivables for the rest of the year?
Yes. Thank you. No, I would not. So receivables in the quarter. I would say working capital was higher in the quarter than what we have seen in previous quarters. And also in relation to sales. As mentioned, that was mainly an effect of higher receivables. And the higher receivables were driven by a very strong finish of the quarter that drove up receivables, which we will see will normalize during the third quarter, and it was not related to any sort of specific initiatives within MedTech.
Got it. Thank you. That's very clear.
There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.
Thank you very much for listening. As I said before, we're very happy with the start of the year and finishing off the first half of 2026 with double-digit growth. We are pleased to see business momentum across all four of our segments. And the active M&A pipeline we have gives an exciting future ahead being able to welcome strong entrepreneurs into the Nextmune family. With that said, I wish all of you a good upcoming summer and look forward to getting back to you during the second half of the year. Thank you.



















